Melanotan II
Melanotan II
Melanotan II is a peptide people usually talk about for Skin Tanning / Photoprotection: Its original intended use to induce melanogenesis for protection against UV radiation. and Erectile Dysfunction: Investigated as a treatment for psychogenic and organic ED. It acts centrally rather than peripherally.. It is still in the FDA review process, so people are watching both the research and the access question closely.
Why does this matter?
Melanotan II matters because a lot of people hear about it online without a clear sense of what it may actually help with. This page gives you the plain-English version first, then shows where the research is strongest, what is still uncertain, and where the peptide stands in the FDA review process.
Molecular weight
~1024.2 g/mol (Da)
Molecular formula
Not specified in the source research
Amino acid count
7
Review date
Before February 2027
Sequence / structure
Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH₂
Other names
Melanotan II, MT-2, MTII, Melanotan 2
Status
Under FDA review for tanning and sexual dysfunction
Melanotan II is a tanning peptide that helps the body make more melanin without needing the same amount of sun exposure. It later became even more interesting because people noticed it could also reduce appetite and noticeably increase sexual arousal. That unusual combination of tanning, body-composition, and sexual-health effects is what keeps it in the conversation.
The quick version before the deep dive
- •People usually talk about Melanotan II for Skin Tanning / Photoprotection: Its original intended use to induce melanogenesis for protection against UV radiation. and Erectile Dysfunction: Investigated as a treatment for psychogenic and organic ED. It acts centrally rather than peripherally..
- •Erectile Dysfunction (ED): Investigated as a treatment for psychogenic and organic ED. It acts centrally rather than peripherally (like PDE5 inhibitors).
- •Activation of the MC1 receptor in melanocytes Helps trigger melanogenesis (the production of melanin), leading to skin pigmentation (tanning) independent of UV exposure.
- •Activation of these receptors in the central nervous system plays a key role in energy homeostasis (appetite suppression) and sexual function. MT-II's binding to MC4R is strongly associated with its erectogenic effects and its ability to increase female sexual arousal.
Deep Dive: Mechanism of Action +
MC1R: Activation of the MC1 receptor in melanocytes stimulates melanogenesis (the production of melanin), leading to skin pigmentation (tanning) independent of UV exposure.
MC3R and MC4R: Activation of these receptors in the central nervous system plays a key role in energy homeostasis (appetite suppression) and sexual function. MT-II's binding to MC4R is strongly associated with its erectogenic effects and its ability to increase female sexual arousal.
It also binds to MC5R, though the clinical significance of this binding is less clear.
Where people usually see it discussed
Investigated Applications +
- Skin Tanning / Photoprotection: Its original intended use to induce melanogenesis for protection against UV radiation.
- Erectile Dysfunction (ED): Investigated as a treatment for psychogenic and organic ED. It acts centrally rather than peripherally (like PDE5 inhibitors).
- Female Sexual Dysfunction (FSD): Investigated for increasing sexual desire and arousal in women.
- Note:* The active metabolite and structural derivative of MT-II, Bremelanotide (PT-141), was specifically developed to isolate the sexual arousal effects from the tanning effects and is FDA-approved.
- Appetite Suppression: Known to reduce food intake in animal models, though not primarily pursued clinically for this indication.
Formal evidence and study snapshots
Deep Dive: Clinical Trials +
Studies demonstrated its efficacy in inducing tanning with minimal sun exposure.
ResearchTanning and sexual dysfunction
Studies demonstrated its efficacy in inducing tanning with minimal sun exposure.
Studies on men with ED showed significant erectile responses.
ResearchTanning and sexual dysfunction
Studies on men with ED showed significant erectile responses.
Clinuvel Pharmaceuticals (originally Epitan) initially worked with Melanotan-related peptides but ultimately focused on Afamelanotide (Melanotan I derivative, Scenesse) for erythropoietic protoporphyria (EPP), moving away from MT-II due to its systemic side effects (nausea, sexual arousal).
ResearchTanning and sexual dysfunction
Clinuvel Pharmaceuticals (originally Epitan) initially worked with Melanotan-related peptides but ultimately focused on Afamelanotide (Melanotan I derivative, Scenesse) for erythropoietic protoporphyria (EPP), moving away from MT-II due to its systemic side effects (nausea, sexual arousal).
Palatin Technologies developed Bremelanotide (PT-141) directly from Melanotan II research. Extensive clinical trials on Bremelanotide eventually led to its FDA approval (as Vyleesi) for generalized hypoactive sexual desire disorder (HSDD) in premenopausal women.
Clinical researchTanning and sexual dysfunction
Palatin Technologies developed Bremelanotide (PT-141) directly from Melanotan II research. Extensive clinical trials on Bremelanotide eventually led to its FDA approval (as Vyleesi) for generalized hypoactive sexual desire disorder (HSDD) in premenopausal women.
What the current safety discussion looks like
- ✓Common: Nausea, flushing, yawning, stretching, loss of appetite.
- ✓Skin: Darkening of existing moles (nevi) and freckles, spontaneous erections.
- ✓Severe Risks: Priapism (prolonged, painful erection) is a recognized risk. There have also been case reports raising concerns about the potential for MT-II to induce changes in existing moles that could be mistaken for melanoma, or potentially promote the growth of existing melanoma cells (though definitive causal links to inducing de novo melanoma are debated, the theoretical risk exists due to MC1R stimulation).
- ✓Renal toxicity has been reported in isolated cases, often associated with unregulated use of high doses.
How the status timeline currently reads
Current status
Current FDA Status: It falls under intense regulatory scrutiny. It is often classified under FDA Category 2 (bulk drug substances nominated for use in pharmacy compounding that raise significant safety concerns).
Current status
Future Actions: There is an anticipated FDA advisory committee meeting scheduled for February 2027 to further review its status and safety concerns.
Current status
Important Note: While MT-II is not approved, its close derivative Bremelanotide (PT-141) IS an FDA-approved drug (Vyleesi) for female sexual dysfunction.
How dosing is usually described
Research protocols
Disclaimer: Melanotan II is not approved for human use. The following reflects common anecdotal protocols found in research and unregulated use, not medical advice. * Dosing typically requires a "loading phase" followed by a "maintenance phase." * Doses are usually administered via subcutaneous injection. * Individual sensitivity varies greatly; users often start with very low doses (e.g., 100-250 mcg) to assess tolerance (especially for nausea) before gradually increasing. * Total cumulative doses required to achieve a desired skin tone vary based on individual skin type (Fitzpatrick scale).
Research protocols only. Not medical advice.
The citations behind the page
Deep Dive: Key Research Papers +
- 1
Dorr, R. T., et al. (1996). "Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study." 1996.
- 2
Wessells, H., et al. (1998). "Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study." 1998.
- 3
Wessells, H., et al. (2000). "Effect of an alpha-melanocyte stimulating hormone analog on penile erection and cardiovascular parameters in dogs and monkeys." 2000.
- 4
Hadley, M. E., & Dorr, R. T. (2006). "Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization." 2006.
Common questions about Melanotan II
What is Melanotan II? +
Melanotan II is Melanotan II, one of the peptides currently under review in connection with tanning and sexual dysfunction.
What is Melanotan II being reviewed for? +
The current advisory review focuses on tanning and sexual dysfunction, with a listed review date of Before February 2027.
Which category does Melanotan II belong to? +
Melanotan II is grouped in this library under Metabolic.
How many amino acids are in Melanotan II? +
Melanotan II is presented here as a 7-amino-acid peptide or peptide analog based on the source research and naming conventions.
What is the sequence or structure note for Melanotan II? +
Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH₂.
What research applications are most associated with Melanotan II? +
Skin Tanning / Photoprotection: Its original intended use to induce melanogenesis for protection against UV radiation., Erectile Dysfunction: Investigated as a treatment for psychogenic and organic ED. It acts centrally rather than peripherally., Female Sexual Dysfunction: Investigated for increasing sexual desire and arousal in women., and Note:* The active metabolite and structural derivative of MT-II, Bremelanotide, was specifically developed to isolate the sexual arousal effects from the tanning effects and is FDA-approved.
How is Melanotan II described as working in the current research? +
Activation of the MC1 receptor in melanocytes Helps trigger melanogenesis (the production of melanin), leading to skin pigmentation (tanning) independent of UV exposure. Activation of these receptors in the central nervous system plays a key role in energy homeostasis (appetite suppression) and sexual function. MT-II's binding to MC4R is strongly associated with its erectogenic effects and its ability to increase female sexual arousal.
How is Melanotan II usually discussed in protocols or treatment plans? +
Melanotan II is most often described with research protocols protocols in the source material.
What does the safety discussion say about Melanotan II? +
Common: Nausea, flushing, yawning, stretching, loss of appetite. Skin: Darkening of existing moles (nevi) and freckles, spontaneous erections.
Continue the comparison
MOTS-c
MOTS-c is a peptide people usually talk about for Obesity and Type 2 diabetes / insulin resistance. It is still in the FDA review process, so people are watching both the research and the access question closely.
Epitalon
Epitalon is a peptide people usually talk about for Aging & Longevity: Used to delay the onset of age-related physical and cognitive decline by preserving cellular lifespan via telomere maintenance. and Sleep Disorders: Applied to correct disrupted circadian rhythms and treat insomnia, leveraging its direct action on the melatonin pathway.. It is still in the FDA review process, so people are watching both the research and the access question closely.
Emideltide
Emideltide is a peptide people usually talk about for Chronic insomnia and Narcolepsy. It is still in the FDA review process, so people are watching both the research and the access question closely.
Get notified when Melanotan II becomes available
Join the waitlist for peptide-specific updates, regulatory milestones, and access news connected to the GobyMeds care pathway.